Ajay Madan, Chief Development Officer at Crinetics Pharmaceuticals, Inc. (CRNX), sold 9,000 shares at $19.88 ($179K) on 2022-03-01, disclosed to the SEC on 2022-03-02.
Scheduled sale ($179k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.